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Available online 24 December 2017Due to the increasing age of our society and a rise in engagement of young people in extreme and/or competitive
sports, both tendinopathies and tendon ruptures present a clinical and ﬁnancial challenge. Tendon has limited
natural healing capacity and often responds poorly to treatments, hence it requires prolonged rehabilitation in
most cases. Till today, none of the therapeutic options has provided successful long-term solutions, meaning
that repaired tendons do not recover their complete strength and functionality. Our understanding of tendon bi-
ology and healing increases only slowly and the development of new treatment options is insufﬁcient.
In this review, following discussion on tendon structure, healing and the clinical relevance of tendon injury, we
aim to elucidate the role of stem cells in tendon healing and discuss new possibilities to enhance stem cell treat-
ment of injured tendon. To date, studies mainly apply stem cells, often in combination with scaffolds or growth
factors, to surgically created tendon defects. Deeper understanding of how stem cells and vasculature in the
healing tendon react to growth factors, common drugs used to treat injured tendons and promising cellular
boosters could help to develop new and more efﬁcient ways to manage tendon injuries.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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In Greek mythology, Achilles, the demigod hero, is almost invulner-
able except for his Achilles heel, whose injury resulted in his death. How
could a tendon injury take such a prominent place in Greekmythology?
This injury was obviously such a crucial and inexplicable event that it
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. This is an open access article underthe ancient Greeks have already wondered how it can happen that
even in young powerful athletes the biggest tendon of man can sud-
denly break. Even today, we cannot explain or foresee when and why
this greatest chord of man tears. Nor can we offer with great degree of
certainty, especially in elderly individuals, complete reconstitution to
normal strength and function of the tendon tissue once it has been
ruptured.
As an integral part of the musculoskeletal system, tendons connect
and transmit forces from muscle to bone. As a result of their composi-
tion and structure they are able to store elastic energy and withstand
the high tensile forces that enable locomotion [1]. With an aging popu-
lation and an increase in sports participation the risk for tendinopathy
or tendon ruptures grows steadily. Approximately 45% of musculoskel-
etal injuries in the US are tendon or ligament injuries [2]. Tendon inju-
ries are most common in the rotator cuff, the Achilles tendon and the
patellar tendon [3] and the pathologies are often based on a degenera-
tive process. Extensor and ﬂexor tendons of the hand are also often sub-
jected to direct lacerations in patients of all ages [2,3].
This review article aims to: (1) provide background information on
tendon structure and the lengthy and insufﬁcient healing process of
tendon after injury including the clinical relevance; (2) highlight the in-
ﬂuence of different types ofmesenchymal stem cells on tendon healing;
(3) summarize how different growth factors involved in tendon healing
inﬂuence mesenchymal stem cells (MSCs) and their capability tothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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on tendon-speciﬁc stem/progenitor cells and vasculature of the tendon
and; (5) discuss the possibility of cellular boosters to amplify the posi-
tive effects of mesenchymal stem cells on tendon healing. In vivo and
in vitro studies have been analyzed and summarized.
1.1. Tendon structure
Tendons are a hierarchically structured dense connective tissues
(Fig. 1), designed to transmit forces between muscle and bone. They
aremainly composed of collagenﬁbers and tenocytes that lie embedded
in a well-ordered extra cellular matrix (ECM), containing high amounts
of proteoglycans. Themain purpose of the collagenﬁbers is to resist ten-
sion, while the proteoglycans provide the viscoelastic properties for the
tendon. Cross-linked tropocollagen form insoluble collagen molecules,
and aggregate into microﬁbrils. These microﬁbrils combined to form ﬁ-
brils that group together into ﬁbers aligning from end to endwithin the
tendon. Fibers group together into a bundle that is ensheathed by a thin
layer of loose connective tissue, known as the endotenon. In addition to
binding the ﬁbers together, the endotenon enables ﬁber groups to glide
over each other and carries blood vessels, nerves and lymphatics to
deeper portions of the tendon [1,4,5]. Fascicles are groups of ﬁber bun-
dles ensheathed by endotenon. The epitenon, a dense ﬁbrillary network
of collagen, binds fascicles together to create the tendon [5]. This com-
plex internal ultrastructure leads to high tensile force and resilience
but also prevents damage and the separation ofﬁbers undermechanical
stress [6].
The collagen network of the tendon matrix forms a regular sinusoi-
dal pattern called “crimps”, which act as a buffer or a shock absorber
within the tendon, permitting small longitudinal elongation of individ-
ual ﬁbrils without permanent damage to the tissue [7]. It has beenFig. 1. A schematic drawing of tendon structure and the localization of tenocytes and TSPCs. T
molecules. Despite tenocytes, tendons contain a pool of stem and progenitor cells. The exact
Locations discussed for different types of stem/progenitor cells in the tendon are the epitenonestimated that these crimps allow 1–3% stretching of the tendon tissue,
and thus, provide a highly efﬁcient “safety measure” for tendons to re-
sist sudden, possibly hazardous tensile strains subjected on them by ex-
cessive contraction or elongation of the attached skeletal muscle [7].
65–80% of the dry mass of tendon consists of collagen, with collagen I
(Col I), accounting for up to 95% of the total collagen, while only 1–2%
consist of elastin (El) [4,8–10]. Besides Col I, the tendon also contains
collagen III (Col III), restricted to the tendon sheets in healthy tendons
[6,11], as well as small amounts of Col V, VI, XII, XIV and XV [6,12].
Together with collagen crimps, elastic ﬁbers made out of El and
tenascin-C (TN-C) in the tendon provide extensibility and ﬂexibility
for the tissue and permit long-range deformability aswell as passive re-
coil without energy input [13].
The ground substance in tendons is built up by proteoglycans like
decorin (Dcn), biglycan (Bgn), ﬁbromodulin (Fmod) and lumican
(Lum), glycoproteins, El and inorganic molecules (copper, manganese
and calcium) [14]. 60 to 80% of the total weight of the ground substance
is water, leading to a hydrophilic, gel-like texture. Thewater binding ca-
pacity of the ground substance improves the elasticity of the tendon,
making itmore resistant against shear and compressive forces, and pro-
vides support to the collagen ﬁbers [5].
Tenocytes and tenoblasts are approximately 90–95% of tendon cells.
Tenocytes, being terminally differentiated, are spindle-shaped, with
elongated nuclei and thin cytoplasmic protrusions anchoring the colla-
gen ﬁbers, while tenoblasts are more roundly shaped with a large,
ovoid nucleus [15]. The discrimination between tenocytes and
tenoblasts is based on cell shape appearance and it is still lacking precise
molecular separation via marker gene expression. Therefore, the exact
tendon cell differentiation process is not fully understood and lagging
far behind the other musculoskeletal lineages. In recent years, several
research papers based on knockout or reporter mouse models havehe tendon is hierarchically structured in fascicles, ﬁbers and ﬁbrils, composed of collagen
location of these TSPCs is not clariﬁed yet and therefore indicated with question mark.
(TSPC type 1), the endotenon (TSPC type 2) and the perivascular region.
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Despite some advancement in recapitulating the discrete molecular
steps of the tenogenic differentiation cascade, the ﬁeld is in need of
identifying speciﬁc surface markers which will allow sorting of tendon
cell populations and in turnwill aid in better characterization of the ten-
don regional cell niches.
The remaining 5–10% of cells in tendon is composed of
chondrocytes, synovial cells of the tendon sheath, capillary endothelial
cells and smooth muscle cells of arterioles.
Tendon cells engage in energy production via theKrebs' cycle, anaer-
obic glycolysis and the pentose phosphate shunt as well as in the bio-
synthesis of collagens and all additional components of the tendon
matrix [1,10,17]. According to the most recent data, most of the tendon
ECM is produced right after birth, thereafter very little ECM production
takes place over the life span of an individual [18].With age, aerobic en-
ergy production and synthesis of ECM components decreases. The shift
to anaerobic energy production leads to the ability to tolerate low oxy-
gen levels, reducing the risk of ischemia and necrosis during extended
periods of stress but also results in a poor and slow healing capacity [5].1.2. Tendon healing
The exactmechanisms of tendon healing are still not completely un-
derstood, due to low number of detailed biochemical, histopathological
and biomechanical studies as well as species-related differences in the
healing process. Most insight has been gained from the analysis of ani-
malmodels of experimentally induced tendon rupture [19,20], or by an-
alyzing human ruptured tendons, but since these are models of acute
injury only, they do not help in understanding the healing process in
tendinopathy [21]. Currently, an optimal experimental model of
tendinopathy is not available for two main reasons. Firstly, due to
poor understanding of the pathogenesis of tendinopathy and especially
of tendinosis and second, as there is no animal with exactly the same
features of human tendons, no one species represents a gold standard
[20]. From a translational point of view, non-human primates represent
the most ideal species as they are the closes to humans in terms of ten-
don anatomy and physiology but their use is limited due to ethical con-
siderations as well as high costs [20]. Small species such as rodents are
the most common animal models. However, their tendons are better
suited to withstand some types of stress such as exposing their extrem-
ities to excessive running or hill work (steep inclination or declination
on treadmill), which leads to no signiﬁcant structural changes in certain
tendons [20]. When treated chemically, by injections of collagenase,
corticosteroids or cytokines, the rodent tendons either do not induce
pathology that replicates the human condition or over-respond by in-
tense inﬂammation followed by progressive tendon reparation [20].Table 1
Phases of tendon healing and growth factors involved.
Repair phase Growth factors
involved
Effects
Inﬂammatory IGF-1
PDGF
TGF-β
VEGF
bFGF
Invasion of inﬂammatory cells and ﬁbroblasts
Chemo attraction, stimulation and proliferation of mac
Chemoattraction, cell migration and proliferation
Angiogenesis, increase in capillary permeability
Cell proliferation
Proliferative IGF-1
PDGF
TGF-β
GDF
Stimulation of migration, division and ECM expression
Stimulation of division, proliferation and ECM express
Cell migration and ECM production
Collagen and GAG production, Cell proliferation and re
Remodeling IGF-1
TGF-β
GDF
ECM remodeling
Collagen synthesis, myoﬁbroblasts, scar formation
Collagen synthesisIt is agreed that during the course of healing, a tendon passes
through three main stages (Table 1 and graphical abstract), which
may overlap, and that their duration depends on location and severity
of the defect [14,22,23].
In the inﬂammation stage, starting directly after injury and lasting
approximately for 3 days, the blood clot, created by the tear that also
ruptures blood vessels, serves as a preliminary scaffold for invading
cells. It then activates the release of chemoattractants from activated
platelets, which initiate the migration of inﬂammatory cells, such as
neutrophils and monocytes, from circulation to the injury site. Mono-
cytes differentiate into macrophages, which digest necrotic material
via phagocytosis and an increase of vasoactive and chemotactic factors
results in the recruitment and activation of tenocytes [22,24,25]. During
this stage, the formation of a vascular network by sprouting angiogene-
sis is initiated, which is essential for the survival of tenocytes engaged in
the synthesis of the new ﬁbrous tissue [26]. The newly formed tissue
mainly consists of ﬁbronectin and Col III, produced by tenocytes at the
injury site [27].
The second proliferation stage lasts up to a few weeks. During this
phase, macrophages release growth factors to direct cell recruitment
and activity [25]. Thereafter, tendon ﬁbroblasts from the epitenon and
the synovial sheath and intrinsic tenocytes from the endotenon are re-
cruited to the injury site to produce Col III, ﬁbronectin and ECM compo-
nents (e.g. proteoglycans) to create an initially unorganized ECM [28,
29]. Then the production of Col III commences and it is replaced by sub-
stantially stronger Col I. Typical features of the proliferation stage are
high cellularity and water absorption.
Following 6–8 weeks, the remodeling stage commences and takes
about 1–2 years, depending upon age and condition of the patient.
This stage can be subdivided into the consolidation stage and thematu-
ration stage. The consolidation stage lasts up to 10 weeks and is charac-
terized by tissue changes from a highly cellular to a more ﬁbrous
appearance. Metabolism of tenocytes is still high in this phase and the
tenocytes and collagen ﬁbers start to align in the direction of stress to
restore tensile strength and tendon stiffness. Furthermore, the synthesis
of Col III is replaced by the synthesis of Col I. Tendon ﬁbroblasts trans-
form to myoﬁbroblast, which contract the large granulation tissue into
substantially smaller, permanent scar tissue. The ﬁnal maturation
stage can take 1–2 years during which a change from ﬁbrous tissue to
a scar-like tendon tissue can be observed. During the course of this
stage, tenocytes metabolism and tendon vascularity decrease [21].
Two different mechanisms, that are most likely acting conjointly, have
been suggested for tendon healing. The extrinsic healing theory states
that ﬁbroblasts and inﬂammatory cells from the periphery and the
blood vessels migrate to the injury site to proliferate and form adhe-
sions. Extrinsic healing is believed to take place mostly in the early
phases of healing. Then intrinsic healing takes over, meaning that cellsReferences
rophages and ﬁbroblasts, expression of growth factors
[253–258]
[259–262]
[135,137,258,260,263,264]
[235,265,266]
[133,135,178]
of tenocytes
ion of tenocytes
alignment
[267,268]
[260,268]
[137,148,258]
[94,263,269–272]
[258]
[161,162,258,263,264]
[94,263,269–272]
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they proliferate, produce and reorganize ECM and give support to the
newly built vascular network [21,29]. There is only very little evidence
on the origin of the participating cells. One study states that initially cir-
culating cells (e.g. from bone marrow) invade the injury site and are
then followed by activated local cells, which participate in the prolifer-
ative and remodeling phase, also conﬁrming the biphasic model of ten-
don healing described above [30].
Various growth factors are involved in the activation and
concertation of cellular processes during the different phases of tendon
healing (Table 1 and graphical abstract) [21,29,31]. The release of
growth factors is triggered ﬁrst from the activated platelets straight
after injury. Furthermore, all tissues contain growth factors in their inac-
tive form and these inactive, “in storage” growth factors are activated in
response to injury. Together, these growth factors initiate the inﬂamma-
tory cascade and recruit more inﬂammatory cells to the site of injury
within hours [24,25,31]. The inﬂammatory cells, in turn, secrete plenty
of growth factors and amplify the inﬂammatory cascade [24,25,31].
The tendon cells located next to the injury site area are also activated
and can produce growth factors, and mechanical loading placed on the
injured tendon can further induce the production of growth factors
[24,25,31]. The exact effect of these growth factors on stem cells in ten-
don healing will be discussed in Section 2 of this review.
The healing ability of tendons is limited and in almost all of the cases,
the biomechanical properties of a healed tendon are not as good as that
of an uninjured tendon [14,29]. Reduced tendon strength leads to thick-
ening and an increased stiffness of the tendon, making it more prone to
re-rupture [14,29].
1.3. Clinical relevance
Classiﬁcation and terminology of different tendon overuse injuries
are still not agreed upon completely. It is commonly accepted that
while tendinitis is accompanied by the inﬁltration of inﬂammatory
cells, the actual inﬂammatory tendinitis is almost non-existent in
human tendon. However, acute, swollen, inﬂammatory reaction can
be seen in epitenon as well as the loose connective tissue surrounding
the tendon [15]. The pathological changes taking placewithin tendon it-
self in overuse injuries is tendinosis. Tendinosis (hypoxic, hyaline and
mucoid degeneration, tendolipomatosis etc.) and acute tendon rupture
aremost likely caused by intratendinous degenerationswithout inﬂam-
mation [32,33]. This view is supported by the fact that histopathologies
of tendinopathy and acute tendon ruptures are identical; the degenera-
tive pathology is just more severe in acute tendon rupture than in
tendinopathy [34,35]. Furthermore, the current paradigm is that the
onset of tendinosis is caused by hypoxia, (i.e. lack of oxygen) in the dis-
eased tendon [32,33]. Angiogenesis is induced by the cells experiencing
hypoxia and in the cells attempt to survive under hypoxia through se-
cretion of soluble growth factors and cytokines, thus recruiting inﬂam-
matory cells [32,33]. Increased numbers of inﬂammatory cells were
seen especially in hypervascular regions of tendinopathy. Due to neither
inﬂammatory exudates nor accumulation of inﬂammatory cells in ten-
donbundles being detected, it was concluded that there is no inﬂamma-
tion in the tendinopathy. For example, Alfredson et al., [36] showed that
no inﬂammatory mediators can be measured in the dialysate from
chronic Achilles tendinopathy obtained by inserting a microdialysis
catheter into the tendon. Furthermore, it should be considered that
the great majority of the cells in tissue remodeling and repair are in-
ﬂammatory cells (mainly macrophages) but their presence does not
necessarily mean inﬂammation. A recent review by Millar et al., [37]
challenges this dominating paradigm by suggesting that the lack of ob-
servation of an acute inﬂammatory inﬁltrate does not exclude a role for
inﬂammation in the etiology of tendinopathy and that there might be
the probability of preceding initial inﬂammation without clinical symp-
toms, ﬁnally leading to tendinopathy or spontaneous tendon rupture.
Tendinopathy is a multifactorial condition and the precise role ofinﬂammation in the tendinopathy process is still debatable and most
likely cannot be viewed under the label of “one-size-ﬁts-all”. Therefore,
future research has to carefully investigate inﬂammatory components
in the various sub-types of tendinopathies.
The term tendinopathy is used throughout this article to describe
overuse disorders affecting tendons, i.e. conditions that do not involve
tendon rupture, but are accompanied by chronic pain.
Healthy tendon has a poor natural healing ability due to
hypocellularity and hypovascularity [38] and very low, almost non-
existent metabolic rate [18], but as long as the ruptured parts remain
in contact to each other and the epitenon is intact, healing without sur-
gical intervention is possible [21]. Therefore, there is an ongoing debate
as to whether to treat ruptured tendons surgically or conservatively, as
these treatments provide almost the same outcome in randomized con-
trolled trials in some tendons such as the Achilles tendon [39,40]. In
Achilles tendon ruptures, surgical intervention reduces the risk of re-
rupturing but on the other hand increases the risk of other complica-
tions such as surgical wound infections [41,42]. With respect to surgical
treatment of rotator cuff, tears does not lead to a better functional out-
come, but reduces pain and disabilities [43].Moreover, the outcome also
depends on patient's age, degree of tendon degeneration and extent of
laceration [44]. Rupture of the patellar tendon leads to abolition of
knee extension [45]. To restore the extensor apparatus of the knee, sur-
gical treatment is inevitable [46] Sutures are the most common ap-
proach to re-establish tendon alignment, whereas bone anchors are
neededwhen there is an avulsion/rupture of tendon frombone. Numer-
ous techniques have been established, each especially adapted to the
speciﬁc tendon. In some cases, tendon autografts may be necessary to
recreate tendon structure, especially in the cases of tendon retraction
or loss. These autografts have to be taken from donor sites, resulting
in the risk of donor site morbidity [25]. Recently, use of allografts to
bridge defects has increased [47,48]. The use of allografts avoids the
problemof donor sitemorbidity but comeswith the concern of immune
rejection and disease transmission [49]. Overall, surgical repair of rup-
tured tendons is often unsuccessful and many become chronic
tendinopathies [2].
However, not only age or overuse can cause tendon disorders, also
several intrinsic factors, including body weight, vascular perfusion, ana-
tomical variants, systemic disease, nutrition and even blood group may
be the causative factors [6,50]. More recently, genetic polymorphisms
associated with an increased risk for Achilles tendinopathy have been
discovered. In the gene encoding for matrix metalloproteinase MMP
13, three different variants have been shown to be associated with
Achilles tendinopathy in a south African Caucasian population [51],
while two variants of the COL5A1 gene also increase the risk for this dis-
ease [52,53].
Acute tendon ruptures and chronic tendinopathies affect a growing
number of people, restricting their quality of life and their capability
to work. Additionally, they are the cause for the enormous budget
spent each year by the worldwide healthcare system.
Hence, it is of great interest to develop new effective therapeutic
treatments, like stem cell-based tissue engineering, growth factor cock-
tails or other drugs, for curing tendon diseases and augmenting tendon
repair.2. Stem cells in tendon
Stem cells are cells with the ability to differentiate into a multitude
of cell types. Due to their potential to differentiate into tenocytes, a
high proliferative and synthetic activity, the secretion of paracrine fac-
tors and the ability to exhibit immunomodulatory effects to promote
tendon regeneration, the use of stem cells in tissue engineering for
tendon repair is of great promise. Stem cells of different origins have
been analyzed for their effect on tendon healing in vitro and in vivo
(Table 2).
Table 2
Effect of different stem cell types in tendon repair.
Cell type Origin of cells Study model Outcome References
Tendon
stem/progenitor
cells (TPSC)
Rat
Rat
Rat
Rat
Rabbit
Human
Rat, patellar tendon, surgical window defect, 1 mm in width,
transplantation of TPSCs in ﬁbrin glue, analysis at 1, 2 and 4
weeks
Rat, patellar tendon, surgical window defect, 1 mm in width,
TPSC-ﬁbrin construct transplantation (with our without
CTGF and ascorbic acid treatment), analysis at 2, 4 and 8
weeks.
Rat; patellar tendon; surgical window defect, 1 mm in
width, transplantation of mock-TDSCs in ﬁbrin glue,
Scx-TPSCs in ﬁbrin glue or scaffold only, analysis at 2, 4 and
8 weeks.
Rat, patellar tendon, surgical window defect, 1 mm in width,
implantation of TPSC cell sheet, analysis 2, 4 and 8 weeks
after surgery.
Rabbit, rotator cuff tendon, surgical defect, 10 × 5 mm,
implantation of TPSC seeded silk-collagen scaffold, analysis
4, 8 and 12 weeks after injury.
Rat, patellar tendon, surgical defect, 2 mm diameter,
implantation of TPSCs with or without ETM gel, analysis 8
weeks after surgery.
Accelerated healing, increased Col production, increased
ultimate stress and Young's modulus at week 4.
Accelerated and enhanced tendon repair by treated TPSC up
to week 8 and 16 compared to untreated TPSC and controls.
Shown by histology, ultrasound imaging and biomechanical
testing.
Better tendon healing in Scx-TPSC group compared to
Mock-TPSC and scaffold only. Shown by histology, viva CT,
biomechanical testing, immunohistochemistry.
Improved healing, increased cellularity, increased ECM
production, no differences in Col expression, higher
ultimate stress and Young's modulus. Shown by histology,
immunohistochemistry and biomechanical testing.
More ingrowth of ﬁbroelastic cells, less inﬁltration of
lymphocytes, denser ECM, more physiological native
tendon structure, higher Col I and Col III production,
increased biomechanical properties. Shown by histology,
immunohistochemistry and biomechanical testing.
Improved tendon healing in ETM group, thicker and more
organized Col ﬁbrils. Shown by histology.
[79]
[83]
[80]
[84]
[72]
[85]
Bone marrow
mesenchymal
stem cells
(BMMSCs)
Rat
Human
Rat, Achilles tendon, surgical window defect,
Injection of BMMSCs,
Analysis after 1, 2 and 4 weeks
Rat, Achilles tendon, Collagenase induced injury;
implantation of BMMSCs; analysis 2, 4 and 6 weeks after
injury.
Rat, Achilles tendon, surgical defect, implantation of
BMMSC-loaded mesh, analysis 6 and 14 days after injury.
Increased tissue repair, higher ultimate failure load,
increased Col production. Shown by histology,
biomechanical testing and RT qPCR
Accelerated healing, increased Col production and better
organization, no differences in biomechanical properties.
Shown by histology, immunohistochemistry and
biomechanical testing
Improved tendon healing, increased ECM production and
better organization. Shown by histology and
immunohistochemistry
Increased load to failure ratio after 2, but not after 4 weeks,
no difference in stiffness, no difference in tissue
organization and Col synthesis. Shown by Histology,
immunohistochemistry and biomechanical testing.
[100]
[101]
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Table 2 (continued)
Cell type Origin of cells Study model Outcome References
Human
Rat
Rat
Rat
Horse
Rat, Achilles tendon, 2.4 mm punch injury, injection of
BMMSCs, analysis 2 and 4 weeks after injury.
Rat, Achilles tendon, complete incision, injection of
normoxic or hypoxic MSCs, analysis 2 and 4 weeks after
incision.
Rat, Achilles tendon, 2.4 mm punch, injection of MSC-eGFP
or MSC-bFGF, analysis 12 weeks after surgery.
Horse, superﬁcial ﬂexor digitorum longus tendon,
spontaneous lesion, injection of MSCs, follow up till 2 years
after treatment.
Faster closure of gap in Achilles tendon, increased ultimate
failure load (hypoxic higher than normoxic), increased
numbers of mature tenocytes, reduced ﬁbrosis, increased
Col I production. Shown by biomechanical testing, histology
and immunohistochemistry.
No differences in load to failure and stiffness, no differences
in Col content and organization. Shown by biomechanical
testing and histology.
Better ultrasound images, return to full exposure, reduced
risk of re-rupture. Shown by ultrasound and follow up
analysis.
[102]
[105]
[103]
[104]
[107]
Adipose-tissue
derived
mesenchymal
stem cells
(ADMSCs)
Horse
Rabbit
Rat
Rabbit
Horse, superﬁcial ﬂexor digitorum longus tendon,
spontaneous lesion, injection of ADMSCs, analysis 9 to 24
weeks after injection.
Rabbit, Achilles tendon, surgical incision, covered with PRP
gel or PRP-ADMSC gel, analysis 4 weeks after surgery.
Rat, supraspinatus tendon, surgical detachment,
implantation of ASDCs in collagen carrier, analysis after 24
h, 1, 2 and 4 weeks.
Rabbit, Achilles tendon, cross section, transplantation of
ADMSCs, analysis after 14 and 28 days.
Horse, superﬁcial ﬂexor digitorum longus tendon,
collagenase induced lesion, injection of MSCs 2 weeks after
lesion induction, Ultrasound every second week till 16
weeks after injection, tendon biopsy 16 weeks after
injection.
Rat, Achilles tendon, collagenase induced lesion, injection of
MSCs 1 week after lesion induction, analysis 4 or 12 weeks
Sonographic improvement of defect, reduced lameness.
Shown by MRT.
Increased tensile strength, more longitudinally arranged
Col ﬁbers, increased Col I production, increased FGF and
VEGF synthesis, decreased TGF-β synthesis. Shown by
biomechanical testing, histology and
immunohistochemistry.
No differences in biomechanical properties, no differences
in Col production. Shown by biomechanical testing and
histology.
Increased structural organization. Shown by histology.
No difference in lesion area, increases linearity of Col ﬁbers,
no differences in Col I and III expression and synthesis.
Shown by ultrasound, histology, immunohistochemistry
and qRT-PCR.
Lower levels of degenerative changes, higher density of
collagen ﬁbers, decreased Col III/Col I ratio. Shown by
histology, immunohistochemistry and RT-PCR.
[122]
[119]
[121]
[118]
(continued on next page)
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Table 2 (continued)
Cell type Origin of cells Study model Outcome References
Horse
Rat
after injection.
[273]
[120]
Stem cells of other
sources
human
(umbilical
vein)
Human
(periodontal
ligament,
gingivial tissue)
Human
(induced
pluripotent,
neural crest)
Human (dental
pulp stem cells
= DSPCs)
Rabbit, Rotator cuff, 5 mm punch, injection of MSCs, analysis
4 weeks after surgery.
Mouse, subcutaneous implantation of alginate microspheres
loaded with TGF-β3 and PDLSCs, GMSCs or BMMSCs,
analysis 8 weeks after implantation.
Rat, patellar tendon, surgical window defect 1 × 4 mm,
implantation of iPSC-NCSCs in ﬁbrin glue or ﬁbrin glue
alone, analysis 4 weeks after surgery.
Mouse, subcutaneous implantation of DSPC-PGA scaffolds
with our without mechanical loading, analysis 8 and 14
weeks after surgery.
Reduced tendon tear size, growth of ﬁbroblastic bundles,
increased Col I production. Shown by histology and
immunohistochemistry.
Neoformation of tendon-like structures in all groups, more
organized ECM and Col in PDLSC group. PDLSCs show best
capability for form tendon-like tissue. Shown by histology
and immunohistochemistry.
Better repair with denser connective tissue and increased
ECM production in iPSC-NCSC group, higher failure load
and Young's modulus. Shown by histology and
biomechanical testing.
Loaded tissue constructs form thicker neotendinous tissue,
faster Col maturation, increased expression of Scx, Tnmd
and TNC. Shown by histology and immunohistochemistry.
[274]
[275]
[276]
[277]
Perivascular cells Rat
Rat
Rat, patellar tendon, window defect 1 × 4 mm, peritenon
sutured or peritenon scratched, analysis 1 and 4 weeks after
surgery.
Rat, patellar tendon defect, transplantation of CTGF
pretreated or untreated CD146+ TSPCs, analysis after 2
weeks
Faster tendon healing in peritenon sutured group. Shown
by macroscopic observation.
Improved tendon healing only in CTGF-TSPC group,
reorganized collagen orientation. Shown by histology.
[131]
[132]
358 M. Schneider et al. / Advanced Drug Delivery Reviews 129 (2018) 352–3752.1. Tendon stem/progenitor cells
In 2007, Bi et al., ﬁrst demonstrated the existence of stem cells in
tendon tissue. They showed that human and mouse tendons contain a
minor cell population which possess clonogenic capability, a distinct
mRNA expression proﬁle, multipotent and have a high proliferation ca-
pability [54]. The existence of stem/progenitor cells (TSPCs) could be
conﬁrmed in various tendons and ligaments from different species
[31,54–64]. They exhibit classical criteria of adult mesenchymal stem
cells, like typical surface antigens, self-renewal, clonogenicity andthree-lineage differentiation (adipogenic, osteogenic and
chondrogenic) [31,54–64]. In contrast toMSCs of other origins, they ex-
press the tendon-related genes scleraxis (Scx), tenomodulin (Tnmd)
[16], cartilage oligomericmatrix protein (Comp) and TN-C [54–59]. Var-
ious studies have focused on the isolation, characterization and theﬁnd-
ing of speciﬁcmarkers of TSPCs (reviewed in [60,61]). TSPCs are positive
for some common stem cell markers, which can also be found on the
surface of other mesenchymal stem cells (MSCs). They express Sca-1,
CD44, CD90, CD90.1, CD105, CD146, Stro-1, nucleostemin, Oct-4 and
SSEA-1 but not CD18, CD31, CD34, CD45, CD106, CD117, CD144 and
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nation between TSPCs, tenoblasts and tenocytes, it is impossible to
isolate pure subsets of cell populations from these differentiation
stages (Fig. 2). The exact role of TSPCs in tendon maintenance and
healing is not completely understood till now. Hence, there is a
great need for in vitro and in vivo studies demonstrating their role
and location.
Recently it was shown that cells simultaneously expressing tendon
and pericyte-associated marker genes are localized in the perivascular
space of tendon tissues, suggesting that the perivascular niche might
be a source of another type of local stem/progenitor cells [55]. Further-
more, it was proposed that there is a regional distribution of different
stem/progenitor cells within tendon, namely in the outer tendon sheet
(TSPC type I) and within the tendon proper (TSPC type II) (Fig. 1) [31,
65]. Comparison between these subpopulations revealed that the
peritenon-derived cells have increased vascular and pericyte markers,
while the tendonproper-derived cells aremore proliferative and exhibit
higher levels of Scx and Tnmd [65]. The study of Bi et al., shows that
TSPCs reside in a niche which consists mostly of ECM. Two ECMmole-
cules, namely ﬁbronectin (Fn) and Bgn seem to play an essential role
in the control of TSPC function. Tendons of double-knockout mice for
Fn and Bgn showed higher cellularity and decreased ﬁbril thickness.
TSPCs of this knockout strain exhibited increased colonogenicity and
proliferation,while the expression of Scx and Tnmdwere reduced, lead-
ing the authors to hypothesize that tendon ECM inﬂuences TSPC self-
renewal and differentiation and that alteration in ECM composition
could lead to tendon malformation and ossiﬁcation. Conforming data
for this hypothesis was also presented in this study, as TSPCs from the
Fn/Bgn knockout mice were more responsive to BMP signaling, which
leads to increased differentiation towards the osteogenic lineage.
Mesenchymal stem cells (MSCs) fromdifferent tissue origins display
common stem cell properties, but still might have tissue speciﬁc charac-
teristics and therefore different functions [66]. Since TSPCs show higherFig. 2.Differentiation of a TSPC to a tenocyte. The expression proﬁle of a TSPC changes during dif
12/13.clonogenicity, proliferation and multi-lineage differentiation potential
compared with bone marrow-derived MSCs (BMMSCs) in vitro [54,60,
67] and also express higher levels of bone morphogenetic protein
(BMP) receptor IA, IB and II [68], TSPCs are most likely a distinct cell
type from BMMSCs. Furthermore, when implanted subcutaneously,
TSPCs formed tendon- and enthesis-like structures, while BMMSC im-
plantation led to the formation of bone and bone marrow-like struc-
tures [54].
As mentioned above, the transplantation of tissues or cells faces
some challenging problems. Transplantation of allogenic cells may
lead to an immune reaction. This problem could be overcome by using
autologous cells, but the retrieval of such cells can cause donor sitemor-
bidity. Another problem that needs to be resolved is that tendon derived
cellsmay undergo phenotypic drift during in vitro expansion.Over time,
cell shape and expression patterns of Col I, Col III and Dcn change in
human tenocyte culture, if cells are cultivated in monolayer [69–71].
One possibility to avoid cell phenotype lost is to mimicking the natural
niche of tendon-derived cells in vitro. In the tendon, tenocytes lay em-
bedded in a dense three-dimensional (3-D) network of collagens,
other ECM components and cells. AAs a result, Schulze-Tanzil et al.,
[72]suggested to cultivate tenocytes in high-density culture, where
they form 3-D pellets. This technique led to stable cell morphology
and expression patterns of Scx, Col I and Col II over 14 days, indicating
that tenocytes retained their phenotypic identity in 3-D culture [72].
An alternative of the 3-D high density culture is a self-assembly model
with tendon-derived cells resulting in 3-D tendon cell sheet structure
that can be subjected to static [289] or even dynamic axial load. Further
proof for the usability of tendon cell sheets formed by TSPCs was pro-
vided by a study showing that the implantation of tendon cell sheets
in a rat Achilles tendon defect improved the overall tendon healing
and reduced the defect size, and resulted in better organized collagen ﬁ-
bers with elongated spindle shaped cells and higher ultimate load, four
weeks after surgery [73].ferentiation to a tenocyte. Tenogenic differentiation ismostly driven by TGF-β2/3 and BMP
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tion on adequate 3-D scaffolds that are similar to native tendon ECM
molecular composition, organization, topography and overall biome-
chanical properties [31,74–76]. TSPC is also a mechanosensitive cell
population [77], hence subjecting the cells to mechanical stimulation
in vitro could provide a relatively simple option to stabilize their charac-
teristics during prolonged cell culture periods.
The number of studies using TSPCs in tendon defectmodels has only
slowly increased. One of the ﬁrst studies by Zhang et al., used human
TSPCs with or without engineered tendonmatrix (ETM) in a rat patellar
tendon window defect. They could show that the implantation, espe-
cially in combination with the ETM, led to increased tendon healing
with the production of thicker and more organized collagen ﬁbrils. In
addition, they also reported that cultivation in ETM stimulates prolifer-
ation and preserves stemness of TSPCs in vitro, further highlighting the
importance of the ECM niche for TSPCs [78]. Most studies analyzing the
effect of TSPC implantation on tendon healing use the rat as amodel or-
ganism. By transplanting GFP-TSPCs in ﬁbrin glue into a rat patellar ten-
don window defect, Ni et al., showed that TSPCs signiﬁcantly enhanced
tendon healing and were observable in the tendon for two weeks after
transplantation. TSPC transplanted tendons exhibited signiﬁcantly in-
creased tendon healing with increased collagen production and ﬁber
alignment, improved cell alignment, increased ultimate stress and a
higher Young's modulus [79].
In an attempt to further improve the positive effects of TSPCs on ten-
don healing different scaffolds or pre-treatments of cells were used. For
example, transduction with Scx prior to implantation enhanced the ex-
pression of tendon-related markers in comparison to Mock-TSPCs. Scx-
TSPCs in a ﬁbrin construct, Mock-TSPCs in a ﬁbrin construct or the ﬁbrin
construct only, were transplanted in a patellar tendon defect. In com-
parison to the Mock-TSPC and ﬁbrin construct only group, healing was
improved in the tendons implantedwith Scx-TSPCs. They exhibited im-
provement in ﬁber arrangement and decreased vascularity and showed
no signs of ossiﬁcation. Regarding biomechanical properties, only at
week four did the Scx-TSPC treated tendons show increased ultimate
stress. At week eight, no differences between the three groupswere ob-
served and Young's modulus did not differ between groups at four or
eight weeks after surgery. The authors try to explain these results
with the usage of older cells for transplantation, which might have
lower differentiation potential. Furthermore, this study does not ad-
dress the question of whether if the transplantation of Scx-TSPCs in-
creases the production of tendon speciﬁc ECM in vivo [80].
Along these lines, recent studies compared native TSPCs derived
from tendon or periodontal ligament as well as tenogenically enforced
BMMSCs via viral Scx over-expression versus BMMSCs for their poten-
tial to repair 3 mm complete defect in a rat Achilles injury model and
showed that implantation of tendon cells is beneﬁcial for late tendon re-
pair in terms of matrix composition and reduced ossiﬁcation [81,82].
In vitro treatment with connective tissue growth factor (CTGF) and
ascorbic acid led to increased tenogenic proliferation, therefore the ef-
fect of such a pre-treatment on TSPCs tendon healing potential was an-
alyzed in a patellar tendon injurymodel. The pre-treatment of TSPCs led
to accelerated tendon healing, eight weeks post-implantation. At
16 weeks, no differences between tendons implanted with pre-treated
TSPCs or untreated TSPCs could be observed. At 8weeks, larger and bet-
ter aligned ﬁbrils were formed and biomechanical properties were in-
creased, indicating that the pro-proliferative effect of CTGF and
ascorbic acid also occurs in vivo and could be useful in accelerating ten-
don healing [83]. In another study with TSPCs, CTGF and ascorbic acid
focussed on forming a TSPC cell sheet by rolling up, which was then
named an engineered scaffold-free tendon tissue (ESFTT) [84]. The
ESFTTwas implanted subcutaneously in nudemice and in a patellar ten-
donwindow defect in rats. The subcutaneous implantation of ESFTT led
to formation of neotendon 12 weeks after surgery.
In the patellar tendonwindow defect, the implantation of ESFTT im-
proved tendon healing signiﬁcantly. Implanted tendons had augmentedECMproduction, better collagen ﬁber alignment, aswell as increased ul-
timate stress and Young's modulus at two, four and eight weeks after
surgery [84].
Shen et al., combined allogeneic TSPCs with a knitted silk-collagen
sponge scaffold and implanted it in rabbit rotator cuff tendons after cre-
ating a surgical defect. The implants did not cause an immunological re-
action but led to increased ﬁbro elastic cell ingrowth and reduced
inﬁltration of lymphocytes, 4 and 8 weeks after surgery. At 12 weeks
after implantation, the allogeneic TSPC-treated group exhibited in-
creased collagen deposition and had better structural and biomechani-
cal properties compared to the control group in which silk-collagen
scaffolds were implanted without TSPCs. How the implanted scaffolds
affected the production and organization of ECM has yet to be clariﬁed
[85].
Asmentioned TSPCs, being a tendon native cell population, hold great
promise for understanding tendon cell biology and for being a cell target
for therapeutic implantation in tendinopathy and possibly in tendon rup-
ture. A remarkable development in this direction was achieved by re-
search on human autologous tenocyte implantation, where tendon cells
were isolated from healthy tendon needle biopsy. After in vitro expan-
sion, the cells were injected into the central tendinopathy of extensor
tendons under ultrasound guidance on a single occasion. A 5 year
follow-up with 16 patients showed signiﬁcantly improved clinical and
MRI tendinopathy scores concluding a long-term positive effect of the
implanted cells [86]. A similar pilot study focusing on treatment of
chronic recalcitrant gluteal tendinopathy concluded that autologous
tenocyte implantation is safe, with improved and sustained clinical out-
come up to 24 months after surgical intervention [87]. At present, this
technology is already approved in Australia (Orthocell).
Despite the promising results indicating the capability of tendon-
derived cells to improve and accelerate tendon healing in experimental
models and to positively inﬂuence tendinopathy in humans, there is still
a great need to analyze how exactly the cells mediate their beneﬁcial ef-
fects to surrounding tissue and how these effects could be further
improved.
2.2. Mesenchymal stem cells
Tendon-derived stem cells are not the only cell source that can be
used for tissue engineering approaches to improve tendon healing, but
also stem cells fromother origins have proven tobepromising. Amongst
the different populations of stem cells, the mesenchymal stem cells
(MSCs) have receivedmost interest in musculoskeletal tissue engineer-
ing. MSCs are stem cells capable of differentiating into cells of one germ
line, mesenchyme, i.e. osteoblasts (bone), chondrocytes (cartilage),
tenocytes (tendon), myocytes (skeletal muscle) or adipocytes (fat).
In the late 1980s, the existence of MSCs in adult tissues was pro-
posed on the basis that subcutaneously or intramuscularly implanted
demineralized bone matrix caused the accumulation of multipotent
progenitors that formed cartilage and/or bone in adult animals [88].
Since then, tissue engineering studies have focused on fabricating
tissue ex vivo, using MSCs of different origins, (e.g. bone marrow, adi-
pose tissue or periodontal ligament) often in combination with suitable
scaffolds. According to the International Society for Cellular.
Therapy, cells must fulﬁll three criteria to be acknowledged asMSCs.
First,MSCsmust be adherent to plasticwhenmaintained in culture. Sec-
ond, MSC populations must be positive for several antigens such as
CD105, CD73 and CD90 but must lack the expression of hematopoietic
antigens like CD45, CD34 and markers for monocytes, macrophages
and B cells. Third, the cells must be able to differentiate at least to oste-
oblasts, adipocytes and chondroblasts under standard in vitro differen-
tiating conditions [89].
2.2.1. Bone marrow-derived MSC
Recent studies have highlighted the ability of BMMSCs to differenti-
ate into various connective tissue types and their usability for tissue
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cell population of the bone marrow are MSCs [93]. They can be easily
obtained via - bone marrow aspirates, e.g. the iliac crest or long bones.
To trigger differentiation of BMMSCs into the tenogenic lineage, treat-
ments with different growth factors, mostly growth differentiation fac-
tors (GDF)/BMPs have been used, since it was shown that implantation
of GDF-5, 6 and 7 leads to ectopic formation of neotendon tissue in vivo
[94]. Treatment with GDF-5 (BMP-14) or GDF-7 (BMP-12) was shown
to induce the expression of tendon-related markers, including Tnmd
and Scx in human and horse BMMSCs, indicating that this treatment
commits BMMSCs into tenogenic lineage in vitro [95,96]. Gene trans-
duction of BMP-2 and active Smad8, GDF-5 or GDF-7 had similar effects
[97,98], but also the transduction with Scx cDNA induced tenogenic dif-
ferentiation in human BMMSCs [99].
In a rat Achilles tendon defect model, the injection of BMMSCs in-
creased overall tendon healing signiﬁcantly. Treated tendons showed
increased production of collagens and a higher ultimate failure load at
1, 2 and 4 weeks after injury. Nevertheless, this study also stresses a
higher capability of TSPCs to improve tendon healing [100]. Various
other studies also used a rat Achilles tendon defectmodel to test the ca-
pacity of human or rat BMMSCs to improve tendon healing (Table 2).
While three studies reported improved tendon healing with increased
biomechanical capacities and collagen production [101−103], other
studies could not demonstrate an effect of BMMSCs on tendon healing,
stressing that there was only differences in biomechanical capacities at
2 but not 4 weeks after surgery and no differences in collagen produc-
tion or ECMorganization. Authors argue that the kind of Achilles tendon
defect that was created (punch versus incision or collagenase induced
lesion) affects the aptitude of BMMSCs for tendon healing [104,105].
Probably, BMMSCs have a temporarily beneﬁcial effect especially in
the early phases of tendon healing. In accordance to this hypothesis,
Chong et al., reported improved tendon healing after BMMSC injection
in a rabbit Achilles tendon injury model, 3 weeks but not 6 or
12 weeks after injury [106].
Likewise one long term study in horses reports a beneﬁcial effect of
BMMSCs in spontaneous lesions of superﬁcial ﬂexor digitorum longus
tendons (SFDLT). Treated horses had improved ultrasound images,
returned to full exposure more quickly and had a lower risk of re-
rupture than untreated animals as long as 2 years after injury [107].
None of these studies reports if BMMSCs undergo tenogenic differenti-
ation in vivo. The main reasons why tenogenic differentiation could
not be proven are that themajority of the implanted cells do not survive
and integrate athat fate tracking of the implanted cells was not carried
out. A recent study has proposed a smart solution by non-invasive
in vivo imaging of technetium-99 m labeled BMMSCs [108].
Since BMMSCs are thought to be hypo immunogenic, allogenic
transplantationmight not require immunosuppression. Another beneﬁt
of this cell types is that they can exert a positive inﬂuence on various
blood cell types leading to an anti-inﬂammatorymilieu during tissue re-
pair by suppressing tissue necrosis factor (TNF)-α and interferon (INF)-
γ, while stimulating the expression of suppressive cytokines like inter-
leukin (IL)-10 [109].
Clinical trials investigating the effects of BMMSCs on tendon healing
are scarce. Improved UCLA (University of California, Los Angeles) score
was shown in 14 patients with complete rotator cuff tear after injection
of non-fractioned iliac-derived BM mononuclear cells, 12 months after
injury. Additionally, MRI showed improved tendon healing and integ-
rity. Only one patient in this study showed aggravation of tendon
strength and pain after 1 year, indicating that the procedure is safe
and provides better functional outcomes than would usually be ex-
pected for such a lesion [110].
One problemwith using BMMSCs for tendons, apart from the painful
BM harvesting procedure, is the formation of calciﬁcation that could
hamper tendon biomechanical properties. Furthermore, lengthy pe-
riods of cell expansion can lead to a phenotypic drift to the osteogenic
lineage and donor age reduces quality of BMMSCs [111].To further evaluate the feasibility of BMMSCs for tendon repair, mul-
ticenter clinical trials should be initiated, since BMMSCs are already ap-
proved for human use in graft versus host disease and in other human
clinical trials.
2.2.2. Adipose tissue-derived mesenchymal stem cells (ADMSCs)
Due to painful harvesting procedures and the low content ofMSCs in
BM aspirates, researchers investigated other possible sources of MSCs,
which should be easy to obtain, create minimal patient discomfort and
yield higher numbers of MSCs to eliminate time consuming expansion
steps in vitro. Adipose tissue presents itself as a good option.
In 2004, Zuk et al., ﬁrst described the existence ofMSCs in adultmes-
enchymal tissue. They isolated cells from lipoaspirates and gave evi-
dence that these cells exhibit multilineage potential in vitro,
differentiating towards the adipogenic, osteogenic, chondrogenic, and
myogenic lineages when cultured in the presence of established
lineage-speciﬁc differentiation factors [112]. Recently, it was found
that a population of Tnmd-positive ADMSCs exists. These cells exhibit
a phenotype very similar to that of TSPCs and can be biochemically in-
duced towards the tenogenic lineage. They express higher levels of
tenogenic genes (Scx, Tnmd, Tn C and Dcn), as well as Col I and Col III
[113]. This ﬁndingmakes adipose tissue an evenmore promising source
of stem cells for the treatment of injured tendon.
In comparison to BMMSCs,MSCs from adipose tissue exhibit less po-
tential for osteogenic and chondrogenic differentiation but are superior
regarding adipogenic potential [114,115] To drive tenogenic differenti-
ation of ADMSCs in vitro, insulin like growth factor (IGF)-1 or
transforming growth factor (TGF)-β in co-culture with primary
tenocytes and GDF-5 have been used successfully [116,117].
Injection of ADMSCs in a rabbit Achilles tendon injurymodel leads to
ameliorated tendon healing. In comparison to untreated groups, ten-
dons of treated rabbits exhibited more organized ECM deposition
[118], while a second study also showed increased tensile strength,
Col I, ﬁbroblast growth factor (FGF) and vascular endothelial growth
factor (VEGF) expression and reduced expression of TGF-β [119]. A sim-
ilar effectwas also reported in a rat Achilles tendon injurymodel. Col III/
Col I ratio was reduced and tendons showed lower levels of degenera-
tion and higher density of collagen ﬁbers in ADMSC-treated group up
to 12 weeks after collagenase induced lesion [120]. In contrast, Mora
et al., reported that the transplantation of ADMSCs in a rotator cuff in-
jury in rats did not beneﬁcially effect biomechanical properties or colla-
gen production, but treated tendons showed less inﬂammation which
could result in more elastic repair and less scarred healing [121].
Race horses often suffer from superﬁcial ﬂexor digitorum longus
tendon (SFDLT) lesions, due to high load during training and racing.
There is evidence that the injection of ADMSCs after spontaneous or
collagenase-induced SFDLT lesion signiﬁcantly improves healing.
Treated horses showed shorter periods of lameness and better organiza-
tion of collagen ﬁbers [122]. Since studies focusing on horses often have
very long follow up examinations and most often do not sacriﬁce ani-
mals at the end of the study, they are especially interesting regarding
long term outcomes of MSC treatments and re-rupture rates.
Like BM-MSCs, AD-MSs are already in clinical trials for other indica-
tions and should also be used in clinical trials analyzing tendon repair.
2.3. Perivascular cells
Perivascular cells (PCs) have drawn attention to tissue engineers in
recent years. They can be isolated frommultiple tissues and play impor-
tant roles in tissue repair, vascular homeostasis and angiogenesis. PCs
can be distinguished mainly in two subtypes: vascular smooth muscle
cells (SMCs) and pericytes. SMCs mainly surround large vessels like ar-
teries and veins and are separated from endothelial cells by the base-
ment membrane and the inner elastic lamina, while pericytes
surround smaller vessels and capillaries and are in direct contact with
ECs. While pericytes are CD146, NG2, PDGFRb, aSMA, CD90,CD73,
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itive for CD34, CD90, CD73, CD105, CD44 and vimentin. Clonal cultures
can be grown from both subtypes [123,124]. Due to their property to se-
cret high amounts of growth factors like heparin-binding epidermal
growth factor (HB-EGF), bFGF and VEGF (reviewed in [125]), which
are known to enhance tissue repair, PCsmake a highly promising candi-
date for stem cell treatments for tendon, muscle or bone regeneration.
Despite that, studies examining the possible application of PCs for tissue
engineering are scarce. In 2008, Crisan et al., published proof of the ex-
istence of PCswithmesenchymal stem cell characteristics, showing that
cultured PCs possessed chondrogenic, adipogenic and osteogenic capac-
ities and expressed MSCmarkers. Furthermore, they stated that human
pericytes, injected in hind limbs of a mouse model of muscular dystro-
phy, form new human myoﬁbers and do so better than skeletal myo-
blasts [123]. Adipose tissue is another possible origin of PCs [126] but
also PCs of the tendon express stem cell-related markers in vitro and
in vivo as well as pericyte-related levels of SMA [55]. Mienaltowski
et al., described two different TSPC populations, one located in the ten-
don proper and one in the peritenon. TSPCs of the peritenon seemed to
be of a more vascular origin, again indicating the existence of
perivascular TSPCs [65].
Subcutaneous implantation of muscle-derived PCs in polyethylene
glycol (PEG)ﬁbrinogen constructs leads to endogenous formation of tis-
sue that contains vessel-like structures and has muscle-like organiza-
tion [127]. Regarding the osteogenic capacity of PCs, Tsang et al.,
reported that human PCs ectopically produce bone when transplanted
subcutaneously in the back of mice [128]. In accordance, human PCs
seeded on an apatite-coated poly(lactic-coglycolic acid) scaffolds signif-
icantly increased ossiﬁcation in a murine calvarial defect and induced
osteogenic growth factor release (BMP2, VEGF) [126]. In a mouse
model, transection of the supraspinatus and the infraspinatus tendon
leads to consistentmuscle atrophy,ﬁbrosis, and fatty inﬁltration, similar
to those observed in human rotator cuff tears [129]. Injection of PCs in
the supraspinatus muscles of mice with rotator cuff tear led to reduced
muscle atrophy and ﬁbrosis, indicating that PCs might be capable of
diminishing ﬁbroadipogenic degeneration [130].
There is evidence that PCs engage in tendon healing andmight be able
to ameliorate it. The epitenon contains a cell pool, which is positive for
P75 (a marker for neural crest stem cells) and SMA. These cells increase
innumber after tendon injury and suturing of the epitenonpromotes ten-
don healing [131]. One additional study reported that CD146+ TSPCs,
which are mainly located perivascularly, pretreated with CTGF, are
capable of improving tendon healing in a rat patellar tendon injury
model, showing in a reconstructed collagen structure. Transplantation
of CD146+ TSPCs did not result in improved collagen structure [132].
3. Inﬂuence of growth factors on stem cells in tendon healing
Asmentioned above, various growth factors are involved in the acti-
vation and concertation of cellular processes during the different phases
of tendon healing (Table 1 and graphical abstract). Tendon injury leads
to the production of multiple growth factors, resulting in increased cel-
lularity and tissue volume [24]. Numerous studies have been published,
with the aim of understanding the inﬂuence of growth factors on ten-
donbiology in vitro and on tendon healing in vivo, someof them, specif-
ically addressing the question on how growth factors inﬂuence stem
cells (reviewed in [31]). Speciﬁc growth factors that are especially im-
portant in tendon healing are, TGF-β, CTGF, BMP-12,−13,−14, bFGF,
platelet derived growth factor (PDGF), IGF-1and VEGF [133–135]. A
summary of their inﬂuence on stemcells during the tendonhealing pro-
cess either in vitro or in vivo is summarized in Table 3.
3.1. TGF-β
TGF-β is active at all stages of tendon healing, as it has multiple and
variable effects, while it is also expressed by most cells involved intendon healing [136,137]. It stimulates extrinsic cell migration, regu-
lates proteinases, terminates cell proliferation and stimulates collagen
production [138–140]. Furthermore, mechanical loading placed on ten-
don induces TGF-β expression and TGF-β-pathway that in turn, regu-
lates ECM and protease expression in the tendon. Thus, TGF-β
signaling pathway is crucial in tendon's adaptation to mechanical load-
ing [141]. On the other hand, TGF-β expression is up-regulated in
tendinopathy and overuse (excessive physical activity) is themajor pre-
disposing factor for the development of tendinopathy [141]. Thus, TGF-
β has been directly implicated in tendon disorders, especially
tendinopathy [141]. It is well established that TGF-β is the growth factor
responsible for scar and ﬁbrous adhesion formation in all tissues in re-
sponse to injury [142].TGF-β is required for the transformation of nor-
mal ﬁbroblasts to contraction-capable myoﬁbroblasts, that produce
the scar tissue [143]. Interestingly, large number of tendon cells in ten-
don sheets and tendon proper, transform to myoﬁbroblasts in chronic
tendinopathy [144,145]. The myoﬁbroblasts are especially abundant in
ﬁbrotic paratenon that contracts around the tendon tissue in chronic
tendinopathy [144,145]. It has been postulated that the shrinkage of
the ﬁbrotic paratenon around diseased tendon is driven by
myoﬁbroblasts and this process could hamper the vascular supply of
the tendon in tendinopathy causing hypoxia that persists in
tendinopathy [144,145]. In mammals, three different isoforms (TGF-
β1, 2 and 3) of the 25 kDa homodimer are expressed, and in mice, the
knockout of each isoform gives rise to a distinct phenotype [146]. TGF-
β1 levels increase very shortly after tendon injury and stay elevated
up to 8weeks in the healing rat patellar ligament [137]. Inﬂexor tendon
repair in the mouse, a biphasic pattern of TGF-β expression was found,
with an early peak of TGF-β1 and a late peak of TGF-β3, accompanied
by an upregulated expression of TGF-β receptors [147]. In vitro, all iso-
forms of TGF-βwere able to upregulate the production of Col I and Col III
by tenocytes isolated from the tendon sheath, the endotenon and the
epitenon [148]. The production and organization of new collagen ﬁbers
is essential for tendon to heal, thus TGF-β seems to play an essential role
in tendon healing. Contrarily, there is also data, stating that TGF-β in-
duces ﬁbrotic scar formation, resulting in adhesion formation [149,
150]. Speciﬁcally, TGF-β1 appears to be responsible for scar and adhe-
sion formation, as treatment with TGF-β1 antibody increased range of
motion within a rabbit model. A combined inﬁltration of TGF-β1 and 2
antibodies did not have beneﬁcial effects [136], leading to the conclu-
sion that TGF-β1 and 2might have detrimental effects on scar and adhe-
sion formation. These ﬁndingswere further underscored by a study that
reports a beneﬁcial effect of antisense oligonucleotide treatment against
TGF-β1, Smad3 and CTGF on ﬂexor tendon healing without negative ef-
fects on tendon biomechanics within a mouse model [151]. Therefore,
the right concentration and combination of different isoforms of TGF-
β has to be found to improve tendon healing.
TGF-β signaling is highly active in tendon cells during development
[152,153] and disruption of TGF-β signaling in TGF-β2 and 3 double
knockout mice, or through deletion of TGF-β receptor type II (TGF-
βRII) results in the loss of almost all tendons in the limbs, trunk, tail
and head [154]. These ﬁndings hint at a possible role of TGF-β in
tenogenic differentiation of TSPCs and other stem cells. It was shown
in one study that TGF-β signiﬁcantly enhances proliferation of TSPCs
in vitro [155], but a second study reported the opposite effect for TGF-
β1 [156]. Since the ﬁrst study does not state which isoform of TGF-β
was used, it is possible that different isoforms inﬂuence TSPC prolifera-
tion in a contrarious manner. Literature agrees that treatment of TSPCs
with TGF-β leads to an increase in Scx expression [156,157], indicating
that TGF-βmight induce tenogenic differentiation of TSPCs. Similar re-
sults have been found for other types of MSCs. Various studies state
that TGF-β treatment induces tenogenic differentiation in BMSCs
[158–162]and two studies report the same effect on ESC [163,164]. In
vivo transplantation of BMSCs transfectedwith TGF-β enhanced tendon
healing in a rabbit Achilles tendon injury model, resulting in raised col-
lagen production, faster ECM production and organization and creation
Table 3
Response of stem cells to growth factors.
Growth
factor
Cell type Study type Result Source
TGF-β MSCs and
TSPCs
In vitro Increased tenogenic potential, upregulation of Scx [157]
TSPCs In vitro Enhanced proliferation [155]
ESCs In vitro Expression of tendon associated genes, tenocyte lineage differentiation [163,164]
ADMSCs In vitro No induction of tenogenic potential [116]
BMSCs In vitro Increased Scx expression and collagen production [160]
BMSCs In vitro Increased proliferation, increased production of Col I and Col III [159]
BMSCs In vivo Ameliorated tendon healing, increased collagen production and biomechanical features [161]
BMSCs
TSPCs
In vivo
In vitro
Ameliorated tendon healing, increased Col I production, more rapid matrix remodeling, larger ﬁber bundles
Loss of stemness, increased expression of Scx, Dcn, TN-C, Col I, Col II and osteonectin, decreased proliferation
[162]
[156]
TGF-β+
VEGF
BMSCs In vivo Accelerated alignment of reconstructed ligament [202]
BMSCs In vivo Ameliorated tendon healing, increased collagen production and biomechanical features [161]
CTGF TSPCs In vivo Better ﬁbril organization, larger ﬁbril size [83]
TSPCs In vitro Increased expression of Scx, Tnmd, Col I and Tn-C [165]
TSPCs
TSPCs
BMSCs
In vivo
In vitro
In vitro
Increased number of CD146+ TSPCs at injury site and enhanced tendon healing
Production of abundant ECM, formation of a cell sheet
Increased Col I and TN-C synthesis, failure to show osteogenic or chondrogenic differentiation
[132]
[84]
[166]
BMP 13 BMSCs
BMSCs
In vitro and
in vivo
In vitro and
in vivo
Increased expression of Scx and Tnmd in vitro, neotendon formation and promoted tendon healing in vivo
Increased expression of Scx and Tnmd in vitro, formation of neo tendinous tissue
[173]
[174]
BMP 12 BMSCs
BMSCs
ADMSCs
BMSCs
BMSCs
In vitro and
in vivo
In vitro and
in vivo
In vitro and
in vivo
In vitro
In vitro
Increased expression of Scx and Tnmd in vitro, enhanced tendon healing with increased matrix production and
elevated expression of tendon markers in vitro
Upregulated expression of Scx, Tnmd, Col I and TN-C in vitro, neo tendon formation in vivo
Upregulated expression of Scx, Tnmd, Col I and TN-C in vitro, neo tendon formation in vivo
Induction of tenogenic differentiation, expression of Tnmd and Dcn
Induction of tenogenic differentiation, expression of Scx and Col I
[171]
[172]
[172]
[95]
[167]
BMP 14 MDMSCs
ADMSCs
TSPCs
In vitro
In vitro
In vitro
Increased failure strength and stiffness of repaired tendon
Increased proliferation, induction of expression of tenogenic markers and ECM components
Loss of stemness, elevated expression of Dcn, Scx and osteonectin, reduced expression of TN-C, Col I and Col II, no
effect on proliferation
[175]
[117]
[156]
BMP 14 +
VEGF
BMSCs In vitro Enhanced tenogenic differentiation [158]
BMP14 +
TGF-β
BMSCs In vitro Enhanced tenogenic differentiation [158]
bFGF TSPCs
BMSCs
AFSCs
ADMSCs
In vivo
In vivo
In vitro
In vitro
Increase in MSCs at injury site, increased expression of Scx and Tnmd, higher histologicals scores and signiﬁcant
improvement in mechanical strength
No beneﬁcial effect on tendon healing, no differences in biomechanical capacities or histology
Induction of tenogenic differentiation, increased expression of Scx and TN-C
Induction of tenogenic differentiation, increased expression of Scx and TN-C
Enhanced proliferation
Promotes maintenance of differentiated cells, reduction of number of TSPCs
[180]
[104,105]
[113]
[113]
(continued on next page)
363M. Schneider et al. / Advanced Drug Delivery Reviews 129 (2018) 352–375
Table 3 (continued)
Growth
factor
Cell type Study type Result Source
TSPCs
TSPCs and
tenocytes
In vitro
In vitro
[155]
[179]
PDGF ADMSCs
ADMSCs
BMSCs
In vitro
In vitro
In vivo
Induction of tenogenic differentiation, increased expression of Scx and TN-C
Enhanced proliferation, tenogenic differentiation, shown by increased expression of Scx and Tnmd
Increased cellularity and hypervascularity 3 weeks after injury, increased production of Col I and Col III
[181]
[278]
[187]
IGF-1 PBMSCs
BMSCs
TSPCs
In vitro
In vivo
In vitro
No inﬂuence on proliferation, no effect on expression of TN-C and Dcn
No improvement in tendon healing and biomechanical properties, no differences in gene expression
Preservation of stemness, slight increase in Scx expression, slight decrease in Col I expression, downregulation of Col
II expression, no effect on proliferation
[279]
[195]
[156]
IGF-1 + TSPCs In vitro Adipogenic differentiation, increased expression of PPAR-γ [196]
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BMSCs. Mechanical strength of tendons treated with TGF-β BMSCs
was also higher than in BMSC treated controls [162]. A combination of
MSC transplantation and TGF-β administration seems to be a promising
approach to treat ruptured tendon, but further studies, especially focus-
ing on possible negative effects of TGF-β (e.g. adhesion and scar forma-
tion) are needed to ensure that TGF-β really and safely augments
tendon healing. One also needs to keep in mind that the clinical trials
with TGF-β for indications outside of the tendon had to halt due to ex-
cessive scar formation [142].
3.2. CTGF/CCN2
Connective tissue growth factor (CTGF/CCN2), a downstreammedi-
ator of TGF-β, andmember of the CCN family, showed persistent upreg-
ulation over 21 days during healing in chicken ﬂexor tendons [134],
while it was moderately expressed at all time points in a rat
supraspinatus injury model [133]. Despite these ﬁndings, very little is
known about the role of CTGF in tendon healing and its inﬂuence on
tenocytes. When treated with CTGF and ascorbic acid in vitro, TSPCs
produce an abundant ECM and thereby form a cell sheet, which can be
used as an engineered tendon tissue transplant [84]. Furthermore,
CTGF is capable of inducing tenogenic differentiation of TSPCs in vitro,
by upregulating the expression of Scx, Tnmd, Col I and TN-C [165]. In
vivo implantation of TSPCs pretreated with CTGF ameliorated tendon
healing in a rat patellar tendon window defect. CTGF TSPC transplanted
tendon exhibited better collagen ﬁber organization and larger ﬁbril size
[83,132]. BMSCs react to CTGF treatment in vitro with an upregulation
of Col I and TN-C expression, and more interestingly fail to undergo
chondrogenic or osteogenic differentiation [166].
3.3. BMPs
BMP-12,−13 and−14 (also known asGDF-7,−6 and−5) also be-
longing to the TGF-β family, are known to stimulate mitogenesis and
tenogenic differentiation of MSCs in vitro [167] and in vivo [94]. During
tendon healing BMPs are elevated at early stages and decrease gradually
over time [133]. While BMP-12,−13 and 14 mainly induce tenogenic
differentiation, BMP-2 drives osteogenic differentiation, assigning it an
important role in enthesis, meaning tendon to bone healing. BMP-2 iseven able to induce newbone formationwithin tendon,which is not de-
sired in intratendinous healing [168–170].
Treatment with BMP-12 induces tenogenic differentiation of BMSCs
and ADMSCs in vitro, showing an upregulated expression of typical ten-
don markers, such as Scx, Tnmd, Col I, TN-C and DCN, while this effect
was also observed in vivo [95,168,171,172]. Pre-treatment of human
BMSCs with BMP-12 followed by transplantation in a rat calcaneal ten-
don defect led to better tendon repair than implantation of untreated
BMSCs. BMP-12 treated cells were largely spindle shaped and produced
well organized ECM,while in the untreated grouponlyminimal tendon-
likemorphologywas exhibited [171]. Furthermore, BMSCs and ADMSCs
produce neotendinous tissue in a nude mouse model after adenoviral
transfectionwith BMP-12 [173]. BMP-13promotes tenogenic differenti-
ation of BMSCs in vitro and also induces neotendon formation by this
cell type [174,175]. Combination of an engineered tendon matrix with
BMP-13 and BMSCswas shown to signiﬁcantly improve tendon healing,
resulting in improved ﬁber alignment, increased ultimate stress and
Young's modulus [174].
BMP-14 is the only BMPwhose effect on TSPCs has been investigated
so far. It appears to have no effect on proliferation but leads to the loss of
stemness of TSPCs. On the other hand, it elevates expression of Dcn, Scx
and osteonectin, but reduces expression of TN-C, Col I and Col II [156]. In
ADMSCs, it increases proliferation and induces tenogenic differentiation
with an upregulation in tenogenic markers and tendon speciﬁc ECM
components [117]. In a tendon in vitro healing model using muscle-
derived MSCs on a gel patch treated with BMP-14, failure strength and
stiffness of the repaired tendon was signiﬁcantly higher than in non-
cell groups. Interestingly, BMSCs treated with BMP-14 had no positive
effect on biomechanical capacities of the repaired tendon [175].
Overall, BMP-12,−13 and−14 are potent inducers of tenogenic dif-
ferentiation in different types of MSCs, but due to a lack of in vivo stud-
ies it has yet to be clariﬁed how they affect TSPCs in tendon healing and
to what extent they beneﬁcially inﬂuence healing capacities of other
MSCs.
3.4. bFGF
bFGF is amember of the heparin-binding growth factor family and is
known to be a potent stimulator of angiogenesis and cellular migration
in vitro and in vivo [176]. bFGF also stimulates proliferation of tendon
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[177]. In a later study, it was found that bFGF mRNA is upregulated in
mature tenocytes, ﬁbroblasts and inﬂammatory cells surrounding the
healing site in the tendon sheath [178]. Regarding the time course of
tendon healing, bFGF levels are elevated at the early stages [133], lead-
ing to the conclusion that bFGF might promote early events in tendon
healing.
In vitro, bFGF enhances proliferation of TSPCs [155] but also pro-
motes the maintenance of differentiated cells and reduces the number
of TSPCs in a TSPC-tenocyte co-culture [179]. Hence, it is likely that
bFGF drives differentiation of TSPCs to tenocytes. In a rat rotator cuff in-
jury model, implantation of a bFGF hydrogel leads to increased ultimate
strength and higher histological scores. In addition, the number of MSCs
was signiﬁcantly increased in the bFGF treated group and that these
cells expressed increased amounts of Scx, indicating that more
tenogenic progenitor cells were generated at the healing sites [180].
While bFGF stimulates tenogenic differentiation of amniotic ﬂuid
stem cells and ADMSCs [181], it seems to have no beneﬁcial effect on
the ability of BMSCs to enhance tendon healing. In two studies using a
rat Achilles tendon defect model, BMSCs lentivirally transfected with
bFGF failed to ameliorate healing of the defect. No differences in biome-
chanical properties or histological appearance could be observed be-
tween treated and untreated groups [104,105].
Since there are very little studies on the effects of bFGF onMSCswith
a focus on tenogenic differentiation and tendon healing, it would be of
interest to analyze if different concentrations of bFGF might generate
different effects. Furthermore, since bFGF is known to be angiogenic, an-
alyzing the effects of bFGF on formation of neovessels in healing tendon
would be advisable.
3.5. PDGF
PDGF is a potent mitogen for cells of mesenchymal origin, including
ﬁbroblasts, smooth muscle cells and glial cells [182,183]. In the healing
canine digital ﬂexor tendon, PDGF was upregulated suggesting a possi-
ble role in tendon healing [184]. Expression of PDGF receptor β is also
elevated in healing tendon and this elevation persists for over
6 months. It was also shown that PDGF administration has a beneﬁcial
effect in a rat patellar tendon defect. Treatment with PDGF increased
tendon healing when it was administered seven days after injury, but
not 3 days after injury [185]. Thus, PDGF might not be essential for the
ﬁrst stage of tendon healing. In vitro, PDGF plays an important part in
tissue remodeling. It was observed to stimulate collagen, non-collagen
protein production and DNA synthesis in a dose dependent manner in
different types of rabbit tendons [186] Therefore, PDGF might play an
important role in the later stages of tendon healing, where an increase
in ECM production was observed.
Furthermore, PDGF increases tenogenic differentiation of ADMSCs
in vitro, causing an upregulation in expression of Scx, Tnmd and TN-C.
PDGF transfected BMSCs seeded on an irradiated Achilles tendon allo-
graft were investigated for their effect on anterior cruciate ligament re-
construction. It was shown that the implantation leads to accelerated
cellular inﬁltration, enhanced collagen production and the initial pro-
motion of angiogenesis [187]. These results also indicate that PDGF
could have beneﬁcial effects on tendon healing after injury.
3.6. IGF-1
IGF-1 is involved in multiple processes in normal body growth and
healing. It mediates all stages of wound healing, especially the inﬂam-
matory and the proliferative phase [188]. It is also upregulated locally
during and after inﬂammation following soft tissue injury, accompanied
by upregulation of its receptors [188–191]. During ligament healing,
IGF-1 mRNA was found to be most upregulated 3 weeks after injury in
the rabbit [188] but in horse ﬂexor tendon, IGF-1 levels had decreased
by approximately 40% after 2 weeks following injury. Increased levelswere found after 4 and 8 weeks within this model [192]. Since the
time course of tendon healing in rabbit and horse is different, these re-
sults are not controversial. IGF-1 mainly seems to stimulate prolifera-
tion and migration of ﬁbroblasts and other cells at the injury site and
to increase production of collagens and other ECM components in
these cells [193,194].
Due to its effects on collagen and ECM production, IGF-1 seems to be
most important in the formation and remodeling stages of healing.
Treatment of TSPCs with IGF-1 led to preservation of stemness, a
slight increase in Scx expression, a slight decrease in Col I expression
and downregulation of Col II expression in vitro. It had no effect on
their proliferation [156]. It is not known how IGF-1 inﬂuences TSPCs
in vivo.
Adenoviral gene transfer of IGF-1 in BMSCs did not increase their
ability to improve tendon healing. Transplantation of non-transduced
BMSCs was as effective in increasing biomechanical properties and
ECM production as transplantation of IGF-1-BMSCs [195].
Treatment or transfection of TSPCs with IGF-1 might actually have
negative effects on tenogenic differentiation. Liu et al., reported, that
combined treatment of rat TSPCs with IGF-1 and BMP-2 signiﬁcantly in-
creases adipogenic differentiation and that they mediate prostaglandin
E (PGE) 2 induced adipogenic differentiation of TSPCs. PGE 2 is sug-
gested to be involved in the pathological changes associated with ten-
don overuse, including osteogenic and adipogenic changes [196].
3.7. VEGF
The angiogenic factor, VEGF, is almost completely downregulated in
healthy tendon but its expression reoccurs during tendinopathy and
tendon healing [197,198]. Neo-angiogenesis could be observed in
human Achilles tendon disorders [199] but no link to VEGF expression
has been made. Despite VEGF having an effect on stromal cells, it is a
highly speciﬁc growth factor for endothelial cells [200], has only a little
direct role in early tendon healing per se, potentially stimulating cellmi-
gration and proliferation. It is most active during the proliferative and
remodeling phase, where it stimulates angiogenesis [197,201]. The
role of neoangiogenesis in tendinopathy and tendon healing will be
discussed more intensely in the latter part of this review.
The inﬂuence of VEGF on MSCs in the context of tendon healing has
mostly been investigated in combination with other growth factors. In
combination with BMP-14, VEGF enhances tenogenic differentiation of
BMSCs in vitro [158]. Two in vivo studies have examined the effect of
BMSCs treated with VEGF and TGF-β on ligament or tendon healing.
In the ﬁrst study, ACL grafts were seeded with TGF-β, VEGF, or TGF-β/
VEGF transfected BMSCs. Three weeks after surgery cellularity and vas-
cularitywere increased in theVEGF andVEGF/TGF-β BMSC grafts. Cellu-
larity and vascularity decreased in all groups over time. At 12 and
24 weeks after surgery, biomechanical properties of VEGF and VEGF/
TGF-β were better than in untreated groups. Co-expression of both
growth factors led to the best outcome for all parameters investigated
[202]. In the second study, human BMSCs were transduced either with
an adenovirus carrying TGF-β, VEGF or both cDNAs. In the co-
expression group, maximum failure load, tendon stiffness and elastic
modulus of the healing tendons were signiﬁcantly increased and there
were signs of accelerated lesion remodeling. VEGF transduced BMSCs
had a negative effect on tendon healing in this study, showing an in-
creased vascularity and decreased collagen content. Biomechanical
properties were not affected by the implantation of VEGF-BMSCs [161].
Since an increase in vascularity is necessary for tendon healing, the
ambivalent actions of VEGF have to be investigated carefully, if it is to
be used as a potential enhancer of tendon healing.
4. Delivery of stem cells to injured tendon
One of the fundamental issues restricting the use of cell-based ther-
apies is the delivery of the cells to the target, as well as their
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into circulation or locally at the site of the injury. The systemic adminis-
tration of stem cells has the problem that the cells do not accumulate at
the site of the injury at therapeutically relevant numbers, whereas local
injection might cause additional damage to the injured tissue and the
stem cell survival is low after local injection due to engraftment prob-
lems [203]. The tendon rupture itself provides an appealing opportunity
to target therapeutics, including stem cells, to the desired location by
simple administration of cells to the circulation. Granulation tissue,
(i.e. the early loose connective tissue that forms between the ruptured
tendon ends) is made out of newly formed, tiny capillaries [33]. These
newly formed angiogenic blood vessels have unique molecular struc-
tures on their surface and provide an opportunity for targeting ligands
that bind to them in an organ-speciﬁc manner [204]. Due to this, a ran-
dom peptide library (1.0 × 109 cyclic peptide ligands) was screened by
in vivo phage display on ruptured Achilles and patellar tendons during
the proliferation phase to ﬁnd systemically administered peptides capa-
ble of homing to the injured sites [204]. The best vascular homing pep-
tides identiﬁed, home to injured tendons up to 200-fold and have been
used successfully for delivery of therapeutic agents, enhancing tissue re-
generation [204–207] Following MSC “painting” of the surface with
multiple copies of these vascular targeting peptides, MSCs delivery
and engraftment were increased by 400% to the infarcted myocardium
[206]. Thus, the vast microvascular network formed by a robust angio-
genic response at the site of tendon rupture offers plenty of molecular
targets for systemically administered ligands to home and deliver
cargo to the ruptured tendon [208]. As these vascular homing peptides
are capable of homing to ruptured tendons and the neovessels are also a
hallmark of tendinopathy, the platform for utilizing the vascular homing
peptide-technology to deliver stem cells to both tendinopathy and
acute, traumatic tendon ruptures is essentially already in place [203,
206] (Fig. 3).
5. Effects of drugs andnovel boosters on stemcells in tendonhealing
To date, drugs to treat tendinopathy are mostly restricted to analge-
sics and anti-inﬂammatory agents (Table 4). Corticosteroid injections
are commonly used to treat tendinopathy in the initial phase due to
their ability to reduce inﬂammation and provide pain relief, evenFig. 3. A schematic drawing on targeted delivery of stem cells to neovessels in tendon injuries. S
regenerating tendon after an acute rupture (or in tendinopathy) provide a platform for target or
with multiple copies of a vascular homing peptide that recognize the angiogenic blood vessels
application: increased number of the stem cells in the target tissue and reduced accumulationthough there are several reports of spontaneous tendon ruptures fol-
lowing the use of local corticosteroid injections [209–211]. Further-
more, data on the utility of local steroid treatment is controversial
[212,213]. Studies using animal models tried to explain the negative ef-
fects of corticosteroids on tendon healing, proposing inhibition of ten-
don cell proliferation, decreased collagen synthesis or increased
collagen breakdown as possible explanations [214–216]. Poulsen et al.,
treated primary human tenocytes with dexamethasome (Dex) and re-
ported that this led to the induction of senescence via the p53/p21 path-
way and further showed that injections led to an increase in p53 and
p21 positive cells in human supraspinatus tendons [217]. To elucidate
to what extent corticosteroids inﬂuence TSPCs and how this could con-
tribute to the poor outcome of tendon healing after local injection, fur-
ther in vitro studies were performed. It became clear that Dex, one of
the most commonly used corticosteroids, reduces TSPC proliferation in
a dose-dependent manner [216,218]. Furthermore, it inhibits tenogenic
differentiation of TPCS and pushes them into an adipogenic or
chondrogenic lineage [218,219].
The implantation of Dex treated TSPCs in nude rats led to extensive
forming of fatty, cartilage-like and bone-like tissue after three weeks
[218]. The increase of adipogenic differentiation is most likely due to
an increase in dickkopf1 expression which leads to inhibition of the
classicalWNT/β-catenin pathway [220]. Trimacinolon, anothermember
of the corticosteroid drug family, is often used to treat pain after tendon
injury. Like Dex, it also induces differentiation of human supraspinatus
tendons into adipocytes and signiﬁcantly reduces their proliferation.
Unfortunately this study did not clarify if the extracted cells were
tenocytes or TSPCs and is likely to be a containing both cell types
[221]. In accordance, treatment of murine mesenchymal stem cells
with Trimacinolon reduced cell proliferation and tenogenic differentia-
tion,while adipogenic differentiationwas enhanced [222]. These results
lead to the assumption that Trimacinolon will also negatively inﬂuence
TSPC proliferation and differentiation.
Bupivacaine, Ropivacaine and Morphine are other analgesics often
used for pain relief (e.g. anterior cruciate ligament reconstruction)
without knowing whether they affect tendon cells. Since it is of great
importance not to compromise the viability or metabolism of TSPCs
within the tendon graft, Haasters et al., investigated the effects of
these three drugs on the viability and metabolism of TSPCs in vitro.peciﬁcmolecular structures on the surface of newly formed angiogenic blood vessels in the
gan-speciﬁc delivery of the systemically administered stem cells. Stem cells are conjugated
and work as an “address tag”. The outcome of the targeted therapy is identical to topical
in the healthy organs.
Table 4
Effects of drugs on tendon stem/progenitor cells.
Drug Effect on TSPCs Source
Dexamethasone Increased synthesis of dickkopf1, inhibition of the
classical WNT/β-catenin pathway, differentiation of
TSPCs to adipocytes
[220]
Inhibition of differentiation to tenocytes,
downregulation of Scx expression
[219]
Low concentrations increase, high concentrations
reduce cell proliferation, upregulation of
non-tenogenic differentiation, formation of fatty
tissues, cartilage-like tissues, and bony tissues
[218]
Dose-dependent inhibition of proliferation, collagen
production, colony formation and expansion
[216]
Trimacinolone Reduced proliferation, increased adipogenic
differentiation
[221]
Bupivacaine Reduced cell viability and metabolism, induction of
apoptosis
[62]
Ropivacaine Reduced cell viability and metabolism, induction of
apoptosis at higher concentrations
[62]
Morphine No cytotoxic effect, no effect on cell metabolism,
survival or apoptosis
[62]
Sclerosin agents Sclerosin injections result in sclerosis, shrinkage of
neovessels in various tendinopathies and have
positive effect on the tendon tissue
[280–285]
Bevacizumab Alone or in combination with platelet rich plasma
accelerates and improves tendon healing in rodent
models
[286,287]
Digoxin Impedes calciﬁcation and promotes tenogenesis of
TSPCs in vitro through inhibition of HIF-2alpha
[288]
Table 5
Novel boosters of tenogenesis.
Component Effect on stem cell Source
Ephrin A4, Ephrin
B2
Eph A4 increases proliferation of aged TSPCs, Eph A4
and Eph B2 increase cell motility, rescue migration
deﬁcit of aged TSPCs and improve their actin
turnover.
[64]
Mohawk Overexpression of Mkx impairs adipogenic and
osteogenic differentiation of MSCs, increases Scx
expression and leads to the formation of cell sheets
with larger Col ﬁbril diameters.
Implantation of Mkx-TSPCs in rat Achilles tendon
injury model leads to increased amounts of mature
Col and better biomechanical capacities.
[225]
Retinoic acid
receptor
agonists
RAR agonists induce Scx expression in TSPCs and
block differentiation to adipocytes, osteocytes or
tenocytes, while maintaining expression of stem cell
markers.
[224]
Rho/Rock agonists Inhibition of Rho/Rock signaling leads to loss of Scx
and Tnmd expression and the tenocyte-like
phenotype of MSC under tenogenic conditions.
Inhibition of Rho/Rock signaling impedes stretch
induced morphological changes of MSCs and
upregulation of tenogenic gene expression
[226]
[227]
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TSPCs and reduce their metabolism, while Morphine had no such effect,
suggesting that morphine is the drug of choice in clinical practice [62].
Overall, there are few drugs used for the treatment of tendinopathy
or tendon injury, despite use in pain relief. However, little is known
about how these drugs affect viability, proliferation and expression pro-
ﬁles of TSPCs. Hence, there is a great need of in vitro studies analyzing if
drugs have undesirable effects on TSPC survival, proliferation and
tenogenic differentiation to enhance tendon repair.
More recently, studies focusing on new cellular boosters that could
enhance tenogenic differentiation of stem cells and therefore increase
the success of stem cell transplantation after tendon rupture have
been published (Table 5). Popov et al., analyzed the effects of age on
Ephrin (Eph) A4 and Eph B2 expression and their effect on self-
renewal, migration and actin turnover of young and aged TSPCs. The
motivation for this study was that aged TSPCs change their expression
of different Eph members, enter senescence earlier and have a self-
renewal deﬁcit as well as dysregulated actin dynamics, cell motility
and cell matrix interactions [63]. In aged TSPCs, Eph A4 and Eph B2
were downregulated signiﬁcantly. They further showed that treatment
with Eph A4 and Eph B2 can overcome the migration deﬁcit of aged
TSPCs and that Eph A4 increases proliferation of aged TSPCs, almost to
the level of young TSPCs [64]. In accordance, another study found that
a disturbed Eph A signaling is related to age-associated senescence in
human cardiac progenitor cells [223]. These ﬁndings indicate that Eph
signaling is important for the maintenance of stem cell characteristics
from different origins. Regarding tendon rupture, implantation of
TSPCs overexpressing Eph is potentially a promising approach.
One problemwith working with TSPCs is that they undergo sponta-
neous differentiation in vitro. Hence the culture steps necessary be-
tween isolation and re-implantation, might lead to the loss of TSPC
stemness. One possible way to circumvent this problem might be the
administration of retinoic acid receptor (RAR) agonists. A study using
high throughput screening identiﬁed RAR agonists as strong inducer
of Scx expression in TSPCs. Further analysis by the authors found that
treatment with a RAR agonist does not inﬂuence cell viability or mor-
phology, but that it leads to an upregulation of Scx expression and
blocks differentiation into osteocytes, adipocytes or tenocytes. Inaddition, the treatment also preserved the expression of stem cell
markers in vitro [224]. Implantation of TSPCs that have not undergone
differentiation during in vitro cultivation, might help to unleash their
complete regeneration potential.
In terms of stem cells of other origins from tendon regeneration,Mo-
hawk (Mkx)might be a promising candidate for inducing tenogenic dif-
ferentiation. Overexpression of Mkx in MSCs impaired adipogenic and
osteogenic differentiation of MSCs and TSPCs. Furthermore, MSCs over-
expressingMkx formed cell sheets with a larger collagen ﬁbril diameter
in vitro and implantation of these cells in a rat Achilles tendon injury
model, increased the amount of mature collagen and enhanced the bio-
mechanical capacities of the repaired tendon in comparison to tendons
treated with mock-MSCs [225].
Activation of the Rho/Rock signaling pathway could be another way
of efﬁciently inducing tenogenic differentiation inMSCs, since inhibition
of this pathway leads to a loss of the elongated phenotype of tenocytes,
a reduction in the expression of Scx and Col I and stretch induced mor-
phological changes seen in tenogenic differentiation are impeded [226,
227].
Despite the fact that the Rho/Rock signaling pathway has been sug-
gested to be involved in the differentiation of MSCs [228,229] there are
no studies investigating the effect of activators of this signaling pathway
on the tenogenic differentiation potential of MSCs.
Overall, we have to deepen our knowledge of molecules and signal-
ing pathways involved in tenogenic differentiation (Fig. 2) to be able to
identify adequate boosters of this process, which can then enhance the
healing potential of MSCs applied in tendon injuries.6. Effects of drugs on vasculature and endothelium in tendon
healing
In the healthy tendon, blood vessels enter the tendon from the
myotendinous junction, the bone insertion site and from the paratenon.
In sheathed tendon, blood vessels only enter the tendon at a fewdistinct
points, while in tendons containing a paratenon, vessels pass through
the tissue more frequently. Since tendons are extended by mechanical
load during movement, the vasculature must be compliant to being
stretched. Hence, the vessels form curves within the tendon tissue
[230]. Due to their limited metabolism and their mechanical function,
tendons contain only very little vasculature. In the adult tendon, the rel-
ative avascularity is simply caused by the fact that themetabolic rate of
tendon is almost non-existent [18,231].
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tological outcome of tendinopathy, (i.e. tendinosis), is the outcome of
persistent hypoxia in the tendon tissue [30,35]. Hypoxic changes are
evenmore severe in tendon rupture than tendinopathy and the hypoxic
changes are the major predisposing factor for acute tendon ruptures
[34,232]. To survive under hypoxia, the cells secrete angiogenic growth
factors (e.g. VEGF) in the hope of inducing angiogenesis to the area re-
quiring oxygen [200,233,234]. Thus, neoangiogenesis is a typical symp-
tom of chronic tendinopathies and tendon rupture, accompanied by an
increase in VEGF expression [235–237]. The role of neovessels for de-
generative tendon disorders is poorly understood (reviewed in [231]).
One theory associates the area of newly grown microvessels with pain
in tendinopathy, since nerve structures are often in close relation [199,
238]. This view is supported by the fact that VEGF also stimulates
nerve (axon) growth and could be the reason why nerves generally fol-
low blood vessels in the human body [239]. Thus in chronic
tendinopathies, hypervascularity is a sign of attempted repair and
might be a contributory factor to pain while in an acute injury, the in-
creased vascularity seems to be essential for tendon repair [26]. When
considering the role of neovessels in tendinopathy, it is fundamental
to understand that the neovessels are non-functional blood vessels,
which do not have proper perfusion and do not deliver oxygen and nu-
trients to the cells needing them, resulting in hypoxia persisting in the
tissue surrounding them [233,234] So, the chronic persistence of
neovessels seen in tendinopathy should be always considered a sign of
failed repair.
Endothelial function is regulated by a ﬁnely balanced equilibrium
between vasorelaxing and vasoconstricting mediators. In these pro-
cesses nitric oxide (NO) seems to have an important role. NO is pro-
duced by two enzymes, NO synthase 1 (NOS1) and NOS2. NOS1 is a
constitutively expressed enzyme that produces tiny amounts of NO to
keep blood vessels open (“dilated”). In turn, NOS2 is an inducible en-
zyme expressed in inﬂammation and produces large quantities of NO.
NO derived from NOS2 reacts with toxic superoxides and stimulates
the production of peroxynitrites and free radicals, eventually predispos-
ing to endothelial dysfunction [240,241]. In normal, un-injured tendon
there is little to no NOS present but after injury, expression of NOS 1,
2 and 3 was upregulated in a rat rotator cuff and Achilles tendon injury
model with a peak, 7 days post injury [242,243] and feeding rats with a
NOS inhibitor, signiﬁcantly reduced tendon healing [244]. VEGF induces
the expression of NOS2 and the increased NO concentrations encoun-
tered in the ruptured tendon after the injury are related to active angio-
genesis and the VEGF-driven vasodilation as well as the inﬂammation
cascade. In human rotator cuff samples, excised during surgical repair,
NOS activity was found in 7 out of 10 samples [245]. Overuse of tendon
also results in an over-expression of NOS isoforms and this might con-
tribute to degenerative changes mediated by increased levels of metal-
loproteinases or cytotoxicity [246,247].
To what extent and howNOs inﬂuence endothelium in tendons and
how this contributes to tendon injury are questions not yet completely
understood. There have been attempts to treat tendinopathies with NO
(reviewed in [244]). In three randomized clinical trials, NO was admin-
istered to the area of tenderness via a glyceril trinitrate (GNT) patch in
three different conditions: tennis elbow, Achilles tendinosis and
supraspinatus tendinosis. In all three conditions, the NO GNT patch led
to enhanced clinical recovery that is demonstrated in reduced pain, in-
creased range of motion and increased strength compared to a placebo
GNT patch.
In summary, one needs to understand that there is neither tissue re-
pair nor regenerationwithout oxygen. In turn, oxygenneeds to be deliv-
ered to tissue undergoing repair by blood vessels. Thus, the blood
vessels are crucial for any tissue repair after injury. The increased vascu-
larity seen in the persistent neovessels in tendinopathy is a sign of failed
repair. It is well established in cancer research that the neovessels are
non-functional; they do not have proper perfusion and do not deliver
oxygen and nutrients to the tissue The hypoxia persists in the tissuesurrounding them [233,234]. Thus, the focus on tendinopathies should
be on stabilizing the non-functional neovessels to provide adequate ox-
ygen and nutrients supply to the tendon. Neovascularization is essential
for the early stages of tendon healing. Hence it might be interesting to
study the effect of drugs that inﬂuence vascularization at different
time points after tendon injury and pursue strategies that stabilize the
vasculature to a functional one [248,249].
Angiogenic inhibitors have been most extensively studied in the
context of cancer, since cutting tumor blood supply is a promising ap-
proach. Many of them have passed or are close to passing FDA approval
and are already used for therapy of cancer or age-related muscular de-
generation [250]. However, anti-angiogenic drugs have been a major
disappointment in the treatment of cancer as the survival beneﬁt de-
rived from them, has been rather minimal [233,234,248]. The mecha-
nism of resistance to the currently available antiangiogenic therapies
in tumors aswell as in retinopathy are actually related to the eradication
of the neovessels, which worsens the underlying ischemia and drives
the formation of new neovessels by alternative molecular mechanisms
[233,234,248]. Thus, the proposed molecular mechanism for future
antiangiogenic therapies is one in which the angiogenic blood vessels
are “normalized” to stable ones to alleviate the hypoxia [233,234,248,
249] The “normalized” blood vessels are functional, they have the
proper perfusion inside them and can carry enough oxygen and nutri-
ents for tissue regeneration to take place [233,234,248]. As described
above, ﬁrst animal studies using anti-VEGF treatment to accelerate ten-
don healing have reported promising results, hence the creation of a
ﬁnely balanced VEGF levels seems to be desirable. However, it is well-
established in other injury models, such as wound and fracture healing
that tissue regeneration cannot be obtained if the injury is treated with
VEGF-inhibitors [251,252].
Pro-anigiogenic substances are of great interest in the early stages of
tendon healing and especially when it comes to transplantation of scaf-
folds, since in this instance, the formation of a robust new vascular net-
work is essential for their incorporation to the healing tissue. Ideally,
scaffolds could be directly loaded with short half-life angiogenic agents,
such as growth factors and they should have desired release kinetics
from the scaffolds.
7. Conclusion
Our understanding of the exact mechanisms of tendon healing and
the precise roles that different cell types play in this process is still lim-
ited and requires forthcoming research focusing at solving concrete is-
sues that have been formulated thanks to the research efforts of the
past decades. At present, the result of treatments for ruptured tendon
is often poor, but stem/progenitor cells hold a great promise for out-
come improvement, although we need to further investigate how they
can be forced or stabilized into the tenogenic lineage and towhat extent
they can be beneﬁcial for early and late tendon healing stages. Stem/
progenitor cells of the tendon tissues have been identiﬁed and studied
in vitro and in vivo; however, we are still lacking tools to segregate
with high level of purity the immature cells from terminally differenti-
ated cells. Special attention should be given in the tendon research to
identify surface markers for cell sorting and to standardize protocols
for enriching and sustaining different tendon-derived cell populations.
In the possible mode of using stem/progenitor cells to augment tendon
healing decorating themwith growth factors or supporting themby cel-
lular boosters might be a goodway to increase their healing potential. A
very promising approach with regards to their homing to the site of in-
jury is to equip them with vascular homing peptides that can guide
them to neoangiogenic activity centers. Regarding the potential of
stem/progenitor cells as a therapeutic agent, it is also very important
to clarify their survival and integration rates as well as to follow their
fate and function over longer periods of time in vivo. When stem/pro-
genitor cells are implemented into various experimental animalmodels
for tendinopathy or tendon injury, we have to carefully and critically
369M. Schneider et al. / Advanced Drug Delivery Reviews 129 (2018) 352–375consider their reﬂection to the human conditions and tendon size di-
mensions. Future efforts to optimize or develop clinically relevant ani-
mal models have to be undoubtedly pursued in order to achieve pre-
clinical models with valid translation to human and veterinary medi-
cine. Another important future perspective for understand what inﬂu-
ences the and inﬂuencing tendon healing process and tendinopathy is
to decipher the current ambivalent roles of inﬂammation and inﬂam-
matory cells, and in the following steps to design and apply strategies
to steer them in order to experimentally examine whether certain in-
ﬂammatory pathways can result in beneﬁcial or detrimental outcomes
of tendon healing or can lead to ampliﬁcation or resolution of
tendinopathy. It is possible that in the next decade that speciﬁc inﬂam-
matory cell types with positive inﬂuence on tendon repair will be iden-
tiﬁed and hence, the ﬁeld can move towards regenerative
immunological strategies to treat certain forms of tendon diseases.
There is already some clinical evidence where autologous implantation
of tendon-derived cells for human tendinopathy shows positive effects
in term of safety and clinical scores. It would be very interesting to in-
vestigate the exact engagement of the transplanted cells that are proc-
essed to repair and their cross-talk to endogenous cells, as well as if
such strategy is foreseeable for treatment of tendon ruptures.
Taken together, Achilles would have been happy to know of the
progress achieved so far but like any true hero, would seek further per-
fection by trying to ﬁnd answers to the many open questions and ex-
ploratory possibilities in the ﬁeld in order to shape up efﬁcient rescue
strategies for ruptured or diseased tendons. This review hopes to en-
courage scientists to engage in studies aiding in better comprehension
of the potential of stem/progenitor cells to improve and speed up the
healing of injured tendons.
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